INVO Fertility Projected for $2.75/Share Loss, 62% Revenue Drop
IVF is trading near its 52-week low of $1.92 (10% above the low) on light trading volume (0.2× avg).
Summary
INVO Fertility Inc is projected to report a significant loss of $2.75 per share and a substantial 62.2% decrease in quarterly revenue to $1.927 million for the period ending December 31, 2025. These analyst expectations, if accurate, signal a material deterioration in the company's financial health, particularly for a company of its small market capitalization. The anticipated loss per share significantly exceeds the current stock price, highlighting severe operational challenges. Traders will be keenly focused on the actual earnings release on April 28 for confirmation and any forward-looking guidance.
At the time of this announcement, IVF was trading at $2.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $1.92 to $384.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.